Boussard & Gavaudan Holding Ltd (EUR): Board Changes

Boussard & Gavaudan Holding Limited
a closed-ended investment company incorporated with limited liability
under the laws of Guernsey with registration number 45582
(the “Company”)

Legal Entity Identifier: 5493002XNM3W9D6DF327

Board Changes

Andrew Howat has today assumed the role of Chairman of the Company, replacing Andrew Henton who is retiring as a director having served on the Board for ten years. The transition is part of a planned succession programme, with Andrew Howat providing an important element of ongoing Board continuity.

The Board is pleased to announce the appointment of Julia Goh as a non-executive director, replacing Andrew Howat as Chair of the Audit Committee. She will also be a member of the Management Engagement Committee. Ms Goh is a Chartered Accountant and has 27 years’ of broad-based financial services experience in London. She was a Managing Director at Barclays Investment Bank from 2010-2018 in various senior front office positions including from 2017 the COO of Global Markets.  She was a Managing Director and the Global Head of Prime Services Risk at Credit Suisse from 1998-2009.  Prior to that, she was a risk manager at Nomura International.  She is currently a non-executive director of Schroder AsiaPacific Fund plc (FTSE 250 investment trust), Pension Insurance Corporation plc and a director of the charity, Children of the Mekong.

The appointment of Ms Goh followed an extensive search process led by a professional search firm.

There is no further information is to be disclosed in respect of paragraphs 9.6.13 (1) - (6) of the FCA Listing Rules.

11 March 2022

For further information, please contact:

Boussard & Gavaudan Holdings Limited
Andrew Howat c/o JTC Fund Solutions (Guernsey) Limited
+44 1481 702 400

Boussard & Gavaudan Investment Management LLP
Emmanuel Gavaudan
+44 203 751 540

Winterflood Securities Limited
Neil Langford
+44 203 100 0000

Attachment

• RNS AMH retirement and succession

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Crypto Price Prediction Flips Bullish and Pepeto Could Be the Biggest Winner of This Rally
• CorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers